December 3, 2012 - Update: Autologous Stem Cell Transplantation for Lymphoma and Myeloma
- The role of autologous stem cell transplantation (ASCT) to treat patients with myeloma
- The role of ASCT to treat patients with lymphoma
- Side effects management and other quality of life issues for ASCT patients
- Key ASCT research topics
- The importance of patient-provider communications
Jonathan W. Friedberg, MD, MMSc
Professor of Medicine and Oncology
Chief, Hematology/Oncology Division
James P. Wilmot Cancer Center
University of Rochester
Rochester, New York
Edward A. Stadtmauer, MD
Professor of Medicine
Leader, Hematologic Malignancies Research Program
Abramson Cancer Center
University of Pennsylvania
Questions Asked by the Myeloma and Lymphoma Communities
- How do you find an experienced autologous stem cell transplant center?
- Is a transplant considered successful or not if a patient makes it a year after transplant and then the disease returns?
- If a patient gets pneumonia easily and often after a donor transplant, what can he or she ask the doctor about activating his or her stem cells?
- If a myeloma patient has renal failure and the autologous stem cell transplant is not effective, what are the treatment options?
- What type of maintenance could be used to help prolong a remission if a patient can?t use lenalidomide (Revlimid®)?
- Do patients receive any drugs prior to stem cell collection that help with the collection of stem cells from the blood?
- If stem cells were collected back in 1999, how long would those cells survive? Would they still be good? Could they ever be used if needed? And what is the shelf life?
- If someone has been treated with the drug ibritumomab tiuxetan (Zevalin®), is he or she able to have a stem cell transplant?
- If a patient harvested stem cells, is it better to get a transplant or just stay on Revlimid?
- Are there any clinical trials that are following stem cell transplant patients to assess side effects and treatments for them?
Sponsors and Supporters
This program is sponsored by The Leukemia & Lymphoma Society and supported by a grant from Sanofi-Aventis.